Drug comparison

Semaglutide vs Liraglutide

JV
John Venzor, DO · Board-certified Internal Medicine
Medically reviewed · Last updated July 6, 2026

Semaglutide and liraglutide are both GLP-1 medications from the same maker, but they differ sharply in dosing frequency. Semaglutide is injected weekly, while liraglutide is a daily injection.

SemaglutideOzempic, Wegovy, Rybelsus
LiraglutideSaxenda, Victoza
Drug class

GLP-1 receptor agonist

GLP-1 receptor agonist

What it is

A once-weekly injectable (also an oral tablet) that curbs appetite and lowers blood sugar, widely used for weight loss and type 2 diabetes.

A once-daily injectable GLP-1, the older option in this class — dosed every day rather than weekly, with generally more modest weight loss.

Category

Weight loss / type 2 diabetes

Weight loss / type 2 diabetes

FDA-approved uses
  • Chronic weight management (as Wegovy)
  • Type 2 diabetes (as Ozempic and Rybelsus)
  • Reducing cardiovascular risk in adults with type 2 diabetes and known heart disease
  • Chronic weight management (as Saxenda)
  • Type 2 diabetes (as Victoza)
  • Reducing cardiovascular risk in adults with type 2 diabetes and known heart disease (Victoza)
Typical dosing
  • Weight management (Wegovy): titrate over ~16–20 weeks to 2.4 mg subcutaneously once weekly
  • Type 2 diabetes (Ozempic): 0.25 mg weekly to start, titrated to 0.5–2 mg once weekly
  • Oral (Rybelsus): 3 mg daily to start, then 7–14 mg once daily on an empty stomach
  • Doses are increased slowly to limit nausea
  • Weight management (Saxenda): titrate weekly from 0.6 mg to a target of 3 mg subcutaneously once daily
  • Type 2 diabetes (Victoza): 0.6 mg daily to start, then 1.2–1.8 mg once daily
  • Doses are increased slowly to limit nausea
Common & serious side effects
Common
  • Nausea
  • Diarrhea
  • Vomiting
  • Constipation
  • Abdominal pain
  • Reduced appetite
Serious
  • Pancreatitis
  • Gallbladder disease
  • Kidney injury from dehydration
  • Diabetic retinopathy complications
  • Severe low blood sugar when combined with insulin or a sulfonylurea
Common
  • Nausea
  • Diarrhea
  • Constipation
  • Vomiting
  • Headache
  • Reduced appetite
Serious
  • Pancreatitis
  • Gallbladder disease
  • Kidney injury from dehydration
  • Severe low blood sugar when combined with insulin or a sulfonylurea
  • Increased heart rate
Who it's for
  • Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition
  • Adults with type 2 diabetes
  • Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition
  • Adults and select adolescents with type 2 diabetes (product-dependent)
Contraindications
  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known serious hypersensitivity to semaglutide
  • Personal or family history of medullary thyroid carcinoma
  • Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • Known serious hypersensitivity to liraglutide
Warnings
  • Risk of pancreatitis — stop if suspected
  • Not for use in type 1 diabetes or diabetic ketoacidosis
  • May delay gastric emptying and affect absorption of oral medications
  • Use in pregnancy is not recommended; stop at least 2 months before a planned pregnancy
  • Risk of pancreatitis — stop if suspected
  • Daily injection required, unlike once-weekly options in the class
  • May delay gastric emptying and affect absorption of oral medications
  • Not for use in type 1 diabetes or diabetic ketoacidosis
Boxed warning
In rodents, semaglutide causes thyroid C-cell tumors. It is unknown whether it causes such tumors, including medullary thyroid carcinoma (MTC), in humans. It is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
In rodents, liraglutide causes thyroid C-cell tumors. It is unknown whether it causes such tumors, including medullary thyroid carcinoma (MTC), in humans. It is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Bottom line: which should I choose?

Choose semaglutide for greater average weight loss and the convenience of one injection a week. Choose liraglutide only if there is a specific reason, such as insurance coverage or a clinician's preference, since it requires daily dosing and generally produces less weight loss. Both cause gastrointestinal side effects and both carry the thyroid C-cell tumor boxed warning.

See if GLP-1 weight-loss treatment is right for you U.S.-licensed clinicians review your intake and prescribe when appropriate.
Get started

Common questions

For most people, semaglutide offers more weight loss and easier weekly dosing. Liraglutide remains a reasonable option in specific situations.
Usually for cost or insurance coverage, or if a clinician has a specific reason to prefer daily dosing.
References
  1. U.S. FDA. Prescribing Information — Wegovy (semaglutide)
  2. U.S. FDA. Prescribing Information — Ozempic (semaglutide)
  3. U.S. FDA. Prescribing Information — Saxenda (liraglutide)
  4. U.S. FDA. Prescribing Information — Victoza (liraglutide)

Care for real conditions, prescribed online

U.S.-licensed clinicians review your intake and prescribe when appropriate — no waiting room.

See if GLP-1 weight-loss treatment is right for you
U.S.-licensed clinicians Transparent pricing No insurance needed